Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Wakamoto Pharmaceutical Co., Ltd. (4512:JPX), powered by AI.
Wakamoto Pharmaceutical Co., Ltd. is currently trading at ¥246. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Wakamoto Pharmaceutical Co., Ltd. on Alpha Lenz.
Wakamoto Pharmaceutical Co., Ltd.'s P/E ratio is 132.5.
“Wakamoto Pharmaceutical Co., Ltd. trades at a P/E of 132.5 (premium valuation) with modest ROE of 0.5%.”
Ask for details →Wakamoto Pharmaceutical Co., Ltd. is a company known for developing and manufacturing pharmaceutical and healthcare products, notably in Japan. Its primary focus is on producing over-the-counter (OTC) medications and pharmaceuticals that enhance digestive health, immune system function, and overall wellness. Among its key products is "Wakamoto," a digestive enzyme supplement that has gained wide recognition for aiding digestion and providing nutritional support. Beyond digestive aids, Wakamoto Pharmaceutical expands its impact across various sectors, including vitamins, nutritional supplements, and skincare products, aligning with the global trend towards preventive health care and wellness maintenance. The company's offerings are distributed through both direct consumer sales and healthcare providers, ensuring widespread access. Established in 1934, Wakamoto Pharmaceutical plays a significant role in the OTC pharmaceuticals market, leveraging its long-standing expertise and quality assurance practices. Its contributions to public health and emphasis on combining traditional and innovative healthcare solutions highlight its importance in the pharmaceutical industry and its commitment to enhancing quality of life for its consumers.
“Wakamoto Pharmaceutical Co., Ltd. trades at a P/E of 132.5 (premium valuation) with modest ROE of 0.5%.”
Ask for details →Wakamoto Pharmaceutical Co., Ltd. (ticker: 4512) is a company listed on JPX in the Healthcare sector (Drug Manufacturers - Specialty & Generic). It has approximately 403 employees. Market cap is $8.5B.
The current price is 246 with a P/E ratio of 132.49x and P/B of 0.74x.
ROE is 0.55% and operating margin is -5.88%. Annual revenue is $7.8B.